New Key Statistics Module, Z-Score and F-Score
NAS:VTRS Key Ratios
| Market Cap $ M | 18,779.46 |
| Enterprise Value $ M | 30,895.36 |
| P/E(ttm) | -- |
| PE Ratio without NRI | 6.49 |
| Forward PE Ratio | 6.52 |
| Price/Book | 1.32 |
| Price/Sales | 1.29 |
| Price/Free Cash Flow | 10.48 |
| Price/Owner Earnings | 23.03 |
| Payout Ratio % | 0.19 |
| Revenue (TTM) $ M | 14,737.00 |
| EPS (TTM) $ | -0.36 |
| Beneish M-Score | -2.91 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -169.57 |
| EV-to-EBITDA | 24.27 |
| PEG | -- |
| Shares Outstanding M | 1,148.59 |
| Net Margin (%) | -2.79 |
| Operating Margin % | 0.89 |
| Pre-tax Margin (%) | -4.49 |
| Quick Ratio | 0.96 |
| Current Ratio | 1.58 |
| ROA % (ttm) | -1.11 |
| ROE % (ttm) | -2.76 |
| ROIC % (ttm) | 0.25 |
| Dividend Yield % | 2.94 |
| Altman Z-Score | 1.06 |
VTRS Number of Guru Trades
VTRS Volume of Guru Trades
Gurus Latest Trades with NAS:VTRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:VTRS is held by these investors
Total 7
Viatris Inc Insider Transactions
No Available Data
Guru Commentaries on NAS:VTRS
Summers Value Fund
Bullish
2026 Q1
What the manager wrote
Viatris is positioned for growth through its partnership with Theravance, particularly with the Yupelri product for COPD. The company reported 12% sales growth for Yupelri in 2025, and we anticipate continued growth driven by increased U.S. hospital adoption and the upcoming launch in China. With patent protection extending through April 2039, Yupelri represents a long-duration and growing cash flow stream. We value the U.S. business at $520 million and the China opportunity at $200 million, supported by Viatris' extensive sales force of over 4,000 reps, which should facilitate a successful launch.
News about NAS:VTRS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers